OBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Obsidian Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$11.94+0.17 (+1.44%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Obsidian Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Obsidian Therapeutics | Industry median |
|---|---|---|
| Market Cap | $11.94K | $166.30M |
| Enterprise Value | $11.94K | $88.19M |
Balance sheet
| Measure | Obsidian Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $0 | $61.43M |
| Net Cash (Debt) | $0 | $15.35M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | $0 | $49.09M |
| Book Value Per Share | $0.00 | $1.37 |
| Tangible Book Value | $0 | $23.52M |
| Working Capital | $0 | $76.81M |
Shares
| Measure | Obsidian Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 1,000 | 58,127,000 |
Calculated by StockData from Obsidian Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.